Dietary cholesterol oxidation products accelerate plaque destabilization and rupture associated with monocyte infiltration/activation via the MCP-1-CCR2 pathway in mouse brachiocephalic arteries: Therapeutic effects of ezetimibe

Journal of Atherosclerosis and Thrombosis

Volumn 19, Issue 11, 2012, Pages 986-998

  Sato, Kei ^a   Nakano, Kaku ^a   Katsuki, Shunsuke ^a   Matoba, Tetsuya ^a   Osada, Kyoichi ^b   Sawamura, Tatsuya ^c   Sunagawa, Kenji ^a   Egashira, Kensuke ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b MEIJI UNIVERSITY   (Japan)

^c NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Cholesterol oxidation products; Inflammation; Matrix metalloproteinase; Monocyte chemoattractant protein 1

Indexed keywords

ANGIOTENSIN II; APOLIPOPROTEIN E; CHEMOKINE RECEPTOR CCR2; CHOLESTEROL; EZETIMIBE; MATRIX METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; OXYSTEROL;

ABSORPTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROTIC PLAQUE; BRACHIOCEPHALIC TRUNK; CELL ACTIVATION; CELL INFILTRATION; CONTROLLED STUDY; HIGH RISK PATIENT; HISTOLOGY; INHIBITION KINETICS; LIPID BLOOD LEVEL; LIPID DIET; LIPID OXIDATION; MALE; MONOCYTE; MOUSE; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

ANIMALS; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS E; AZETIDINES; BRACHIOCEPHALIC TRUNK; CHEMOKINE CCL2; CHOLESTEROL, DIETARY; FLOW CYTOMETRY; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; IMMUNOHISTOCHEMISTRY; LIVER; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, KNOCKOUT; MONOCYTES; OXIDATION-REDUCTION; OXIDATIVE STRESS; PLAQUE, ATHEROSCLEROTIC; RECEPTORS, CCR2; STEROLS;

EID: 84870749692     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.13391     Document Type: Article

References (34)

1. Steinberg D. Lewis A: Conner memorial lecture. Oxidative modification of ldl and atherogenesis. Circulation, 1997; 95: 1062-1071
2. Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circulation, 2002; 105: 1135-1143
3. Libby P, Aikawa M: Stabilization of atherosclerotic plaques: New mechanisms and clinical targets. Nat Med, 2002; 8: 1257-1262
4. Brown AJ, Jessup W: Oxysterols and atherosclerosis. Atherosclerosis, 1999; 142: 1-28
5. Carpenter KL: Good cop, bad cop: An unsolved murder. Are dietary cholesterol oxidation products guilty of atherogenicity? Br J Nutr, 2002; 88: 335-338
6. Staprans I, Pan XM, Rapp JH, Feingold KR: Oxidized cholesterol in the diet is a source of oxidized lipoproteins in human serum. J Lipid Res, 2003; 44: 705-715
7. Garcia-Cruset S, Carpenter KL, Guardiola F, Stein BK, Mitchinson MJ: Oxysterol profiles of normal human arteries, fatty streaks and advanced lesions. Free Radic Res, 2001; 35: 31-41
8. Staprans I, Pan XM, Rapp JH, Grunfeld C, Feingold KR: Oxidized cholesterol in the diet accelerates the development of atherosclerosis in ldl receptor-and apolipoprotein e-deficient mice. Arterioscler Thromb Vasc Biol, 2000; 20: 708-714
9. Staprans I, Pan XM, Rapp JH, Feingold KR: Oxidized cholesterol in the diet accelerates the development of aortic atherosclerosis in cholesterol-fed rabbits. Arterioscler Thromb Vasc Biol, 1998; 18: 977-983
10. Falk E, Shah PK, Fuster V: Coronary plaque disruption. Circulation, 1995; 92: 657-671
11. Gustafson B: Adipose tissue, inflammation and atherosclerosis. J Atheroscler Thromb, 2010; 17: 332-341
12. Altmann SW, Davis HR Jr, Zhu LJ, Yao X, Hoos LM, Tetzloff G, Iyer SP, Maguire M, Golovko A, Zeng M, Wang L, Murgolo N, Graziano MP: Niemann-pick c1 like 1 protein is critical for intestinal cholesterol absorption. Science, (New York, N.Y. 2004; 303: 1201-1204)
13. Staprans I, Pan XM, Rapp JH, Moser AH, Feingold KR: Ezetimibe inhibits the incorporation of dietary oxidized cholesterol into lipoproteins. J Lipid Res, 2006; 47: 2575-2580
14. Davis HR Jr, Compton DS, Hoos L, Tetzloff G: Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in apoe knockout mice. Arterioscler Thromb Vasc Biol, 2001; 21: 2032-2038
15. Nakagami H, Osako MK, Takami Y, Hanayama R, Koriyama H, Mori M, Hayashi H, Shimizu H, Morishita R: Vascular protective effects of ezetimibe in apoe-deficient mice. Atherosclerosis, 2009; 203: 51-58
16. Rosenfeld ME, Polinsky P, Virmani R, Kauser K, Rubanyi G, Schwartz SM: Advanced atherosclerotic lesions in the innominate artery of the apoe knockout mouse. Arterioscler Thromb Vasc Biol, 2000; 20: 2587-2592
17. Johnson J, Carson K, Williams H, Karanam S, Newby A, Angelini G, George S, Jackson C: Plaque rupture after short periods of fat feeding in the apolipoprotein e-knockout mouse: Model characterization and effects of pravastatin treatment. Circulation, 2005; 111: 1422-1430
18. Gough PJ, Gomez IG, Wille PT, Raines EW: Macrophage expression of active mmp-9 induces acute plaque disruption in apoe-deficient mice. J Clin Invest, 2006; 116: 59-69
19. Clarke MC, Figg N, Maguire JJ, Davenport AP, Goddard M, Littlewood TD, Bennett MR: Apoptosis of vascular smooth muscle cells induces features of plaque vulnerability in atherosclerosis. Nat Med, 2006; 12: 1075-1080
20. Cicha I, Regler M, Urschel K, Goppelt-Struebe M, Daniel WG, Garlichs CD: Resveratrol inhibits monocytic cell chemotaxis to mcp-1 and prevents spontaneous endothelial cell migration through rho kinase-dependent mechanism. J Atheroscler Thromb, 2011; 18: 1031-1042
21. Zhang S, Wang X, Zhang L, Yang X, Pan J, Ren G: Characterization of monocyte chemoattractant proteins and cc chemokine receptor 2 expression during atherogenesis in apolipoprotein e-null mice. J Atheroscler Thromb, 2011; 18: 846-856
22. Ishibashi M, Egashira K, Zhao Q, Hiasa K, Ohtani K, Ihara Y, Charo IF, Kura S, Tsuzuki T, Takeshita A, Sunagawa K: Bone marrow-derived monocyte chemoattractant protein-1 receptor ccr2 is critical in angiotensin ii-induced acceleration of atherosclerosis and aneurysm formation in hypercholesterolemic mice. Arterioscler Thromb Vasc Biol, 2004; 24: e174-178
23. Osada K, Kodama T, Minehira K, Yamada K, Sugano M: Dietary protein modifies oxidized cholesterol-induced alterations of linoleic acid and cholesterol metabolism in rats. J Nutr, 1996; 126: 1635-1643
24. Ni W, Kitamoto S, Ishibashi M, Usui M, Inoue S, Hiasa K, Zhao Q, Nishida K, Takeshita A, Egashira K: Monocyte chemoattractant protein-1 is an essential inflammatory mediator in angiotensin ii-induced progression of established atherosclerosis in hypercholesterolemic mice. Arterioscler Thromb Vasc Biol, 2004; 24: 534-539
25. Sato Y, Nishimichi N, Nakano A, Takikawa K, Inoue N, Matsuda H, Sawamura T: Determination of lox-1-ligand activity in mouse plasma with a chicken monoclonal antibody for apob. Atherosclerosis, 2008; 200: 303-309
26. Satoh K, Nigro P, Matoba T, O'Dell MR, Cui Z, Shi X, Mohan A, Yan C, Abe J, Illig KA, Berk BC: Cyclophilin a enhances vascular oxidative stress and the development of angiotensin ii-induced aortic aneurysms. Nat Med, 2009; 15: 649-656
27. Usui S, Hara Y, Hosaki S, Okazaki M: A new on-line dual enzymatic method for simultaneous quantification of cholesterol and triglycerides in lipoproteins by hplc. J Lipid Res, 2002; 43: 805-814
28. Ishigaki Y, Katagiri H, Gao J, Yamada T, Imai J, Uno K, Hasegawa Y, Kaneko K, Ogihara T, Ishihara H, Sato Y, Takikawa K, Nishimichi N, Matsuda H, Sawamura T, Oka Y: Impact of plasma oxidized low-density lipoprotein removal on atherosclerosis. Circulation, 2008; 118: 75-83
29. Yagi K: Assay for blood plasma or serum. Methods Enzymol, 1984; 105: 328-331
30. Swirski FK, Libby P, Aikawa E, Alcaide P, Luscinskas FW, Weissleder R, Pittet MJ: Ly-6chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J Clin Invest, 2007; 117: 195-205
31. Tacke F, Alvarez D, Kaplan TJ, Jakubzick C, Spanbroek R, Llodra J, Garin A, Liu J, Mack M, van Rooijen N, Lira SA, Habenicht AJ, Randolph GJ: Monocyte subsets differentially employ ccr2, ccr5, and cx3cr1 to accumulate within atherosclerotic plaques. J Clin Invest, 2007; 117: 185-194
32. Crisby M, Nordin-Fredriksson G, Shah PK, Yano J, Zhu J, Nilsson J: Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: Implications for plaque stabilization. Circulation, 2001; 103: 926-933
33. Kai H, Ikeda H, Yasukawa H, Kai M, Seki Y, Kuwahara F, Ueno T, Sugi K, Imaizumi T: Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol, 1998; 32: 368-372
34. Inokubo Y, Hanada H, Ishizaka H, Fukushi T, Kamada T, Okumura K: Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am Heart J, 2001; 141: 211-21